Antisense-mediated VEGF suppression in bladder and breast cancer cells

Cancer Letters

Volumn 212, Issue 1, 2004, Pages 95-103

  Förster, Yvonne ^a   Meye, Axel ^a   Krause, Sabine ^a   Schwenzer, Bernd ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Antisense oligonucleotides; AS ODN, antisense oligodeoxynucleotides; BCa, bladder cancer; Bladder cancer; ELISA, enzyme linked immunosorbent assay; FITC, fluorescein isothiocyanate; PBGD, porphobilinogen deaminase; Transfection; VEGF

Indexed keywords

VASCULOTROPIN;

ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EVALUATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CARCINOMA; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MINK CELL FOCUS-FORMING VIRUS;

EID: 3042771836     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.02.020     Document Type: Article

References (50)

1. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:1997;4-25
2. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5:1991;1806-1814
3. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:1991;11947-11954
4. 145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272:1997;7151-7158
5. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Fed. Am. Soc. Exp. Biol. J. 13:1999;9-22
6. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 9:1999;211-220
7. Ferrara N. Vascular endothelial growth factor. Eur. J. Cancer. 32A:1996;2413-2422
8. Petrova T.V., Makinen T., Alitalo K. Signalling via vascular endothelial growth factor receptors. Exp. Cell. Res. 253:1999;117-130
9. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor familiy. Cardiovasc. Res. 49:2001;568-581
10. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:1992;65-71
11. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorgenesis. Cell. 86:1996;353-364
12. Marmé D. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J. Urol. 14:1996;166-174
13. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039
14. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 79:1997;233-269
15. Zhang H.T., Craft P., Scott P.A., Ziche M., Weich H.A., Harris A.L., Bicknell R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells. J. Natl Cancer Inst. 87:1995;213-219
16. Detmar M., Velasco P., Richard L., Claffey K.P., Streit M., Riccardi L., Skobe M., Brown L.F. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinoma. Am. J. Pathol. 156:2000;159-167
17. Luo J., Guo P., Matsuda K., Truong N., Lee A., Chun C., Cheng S., Korc M. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorgenicity in vivo. Int. J. Cancer. 92:2001;361-369
18. Sato K., Sasaki R., Ogura Y. Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J. Exp. Med. 185:1998;173-184
19. Morino F., Tetsuji T., Tsuchida T., Handa A., Nagata J., Tomii Y., Kijima H., Yamazaki H., Watanabe N., Mastuzaki S., Ueyama Y., Nakamura M. Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line. Int. J. Oncol. 17:2000;495-499
20. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:1993;841-844
21. Borgstrom P., Hillan K.J., Sriramarao P., Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56:1996;4032-4039
22. Melnyk O., Shuman M.A., Kim K.J. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. 56:1996;921-924
23. Vitaliti A., Wittmer M., Steiner R., Wyder L., Neri D., Klemenz R. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res. 60:2000;4311-4314
24. Masood R., Cai J., Zheng T., Smith D.L., Naidu Y., Gill P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS - Kaposi sarcoma. Proc. Natl Acad. Sci. USA. 94:1997;979-984
25. Ciardiello F., Bianco R., Damiano V., Fontanini G., Caputo R., Pomatico G., De Placido S., Bianco A.R., Mendelsohn J., Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6:2000;3739-3747
26. Cheng S.-Y., Huang H.J.S., Nagane M., Ji X.-D., Wang D., Shih C.C.-Y., Arap W., Huang C.-M., Cavenee W.K. Suppression of glioblastoma angiogenicity and tumorgenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA. 93:1996;8502-8507
27. Nakashima T., Hudson J.M., Clayman G.L. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck. 22:1999;483-488
28. Scherr M., Rossi J.J., Sczakiel G., Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res. 28:2000;2455-2461
29. Scherr M., Rossi J.J. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligonucleotides in murine cell extracts. Nucleic Acids Res. 26:1998;5079-5085
30. Vickers T.A., Wyatt J.R., Freier S.M. Effects on RNA secondary structure on cellular antisense activity. Nucleic Acids Res. 28:2000;1340-1347
31. Sohail M., Southern E.M. Hybridization of antisense reagents to RNA. Curr. Opin. Mol. Ther. 2:2000;264-271
32. Smith L., Andersen K.B., Hovgaard L., Jaroszewski J.W. Rational selection of antisense oligonucleotide sequences. Eur. J. Pharm. Sci. 11:2000;191-198
33. Fujiyama C., Jones A., Fuggle S., Bicknell R., Cranston D., Harris A.L. Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br. J. Cancer. 84:2001;558-564
34. Zuker M., Mathews D.H., Turner D.H. Algorithms and thermodynamics for RNA secondary structure prediction: a practical guide. Barciszewski J., Clark B.F.C. RNA Biochemistry and Biotechnology. NATO ASI Series. 1999;11-43 Kluwer, Dordrecht
35. Mathews D.H., Sabina J., Zuker M., Turner D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288:1999;911-940
36. Wellmann S., Taube T., Paal K., Graf V., Einsiedel H., Geilen W., Seifert G., Eckert C., Henze G., Seeger K. Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin. Chem. 47:2001;654-660
37. Füssel S., Sickert D., Meye A., Klenk U., Schmidt U., Schmitz M., Rost A.-K., Weigle B., Kiessling A., Wirth M.P. Multiple tumour marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int. J. Oncol. 23:2003;21-29
38. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Miller W., Lipman D.J. Gapped BLAST and PSJ-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:1997;3389-3402
39. Grunstein J., Masbad J.J., Hickey R., Giordano F., Johnson R. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell. Biol. 20:2000;7282-7291
40. Li N.-C., Kanda K., Fukumori T., Inoue Y., Nishitani M., Kanayama H., Kagawa S. Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer. Urol. Oncol. 6:2001;10-15
41. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 4:1993;1317-1326
42. Ishii H., Oota I., Takuma T., Inomata K. Developmental expression of vascular endothelial growth factor in the masseter muscle of rats. Arch. Oral Biol. 46:2001;77-82
43. Kraemer K., Fuessel S., Schmidt U., Kotzsch M., Schwenzer B., Wirth M.P., Meye A. Antisense-mediated hTERT inhibition impairs specifically growth of human bladder cancer cells. Clin. Cancer Res. 9:2003;3794-3800
44. Patzel V., Steidl U., Kronenwett R., Haas R., Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribo-nucleotides at high statistical probability. Nucleic Acids Res. 27:1999;4328-4334
45. Bashirullah A., Cooperstock R.L., Lipshitz H.D. RNA localization in development. Annu. Rev. Biochem. 67:1998;335-394
46. Decker C.J., Parker R. Diversity of cytoplasmic functions for 3′ untranslated region of eukaryotic transcripts. Curr. Opin. Cell. Biol. 7:1995;386-392
47. Monia B.P., Johnson J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1996;668-675
48. Mologni L., Nielsen P.E., Gambacorti-Passerini C. In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. Biochem. Biophys. Res. Commun. 264:1999;537-543
49. O'Dwyer P.J., Stevenson J., Gallagher M., Cassella A., Vasilevskaya I., Monia B.P., Holmlund J., Dorr F.A., Yao K.S. C-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS-5132 (CGP-69846A). Clin. Cancer Res. 5:1999;3977-3982
50. Fuessel S., Kueppers B., Ning S., Kotzsch M., Kraemer K., Schmidt U., Meye A., Wirth M.P. Systematic in vitro-evaluation of survivin-directed antisense oligodeoxynucleotides in bladder cancer cells. J. Urol. 2004;. in press